Literature DB >> 16904394

The role of outer membrane and efflux pumps in the resistance of gram-negative bacteria. Can we improve drug access?

H Nikaido1.   

Abstract

Many antibiotics inhibit gram-negative bacteria less effectively than gram-positive bacteria, because the outer membrane permeability barrier allows only a slow influx of drugs, and the small number of drug molecules that traversed the outer membrane are efficiently inactivated or pumped out back into the medium, the last-mentioned process often catalyzed by widely distributed multidrug efflux pumps. Paradoxically, drugs of advanced design that are not inactivated enzymatically, such as beta-lactamase-stable lactams and fluoroquinolones, tend to select for more resistant mutants which overexpress these pumps. The drug-hypersensitive phenotype of efflux-deficient mutants suggests that inhibition of the pumps may be a good way not only to combat resistance of this type, but also to make 'intrinsically' resistant gram-negative bacteria susceptible to a wide range of drugs. Alternatively, the outer membrane can be permeabilized by cationic peptides, thereby sensitizing bacteria especially to lipophilic antibiotics.

Entities:  

Year:  1998        PMID: 16904394     DOI: 10.1016/s1368-7646(98)80023-x

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  21 in total

1.  Cross-linked complex between oligomeric periplasmic lipoprotein AcrA and the inner-membrane-associated multidrug efflux pump AcrB from Escherichia coli.

Authors:  H I Zgurskaya; H Nikaido
Journal:  J Bacteriol       Date:  2000-08       Impact factor: 3.490

Review 2.  Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 3.  Molecular basis of bacterial outer membrane permeability revisited.

Authors:  Hiroshi Nikaido
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

4.  Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.

Authors:  Khisimuzi E Mdluli; Pamela R Witte; Toni Kline; Adam W Barb; Alice L Erwin; Bryce E Mansfield; Amanda L McClerren; Michael C Pirrung; L Nathan Tumey; Paul Warrener; Christian R H Raetz; C Kendall Stover
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  MtrR modulates rpoH expression and levels of antimicrobial resistance in Neisseria gonorrhoeae.

Authors:  Jason P Folster; Paul J T Johnson; Lydgia Jackson; Vijaya Dhulipali; David W Dyer; William M Shafer
Journal:  J Bacteriol       Date:  2008-10-31       Impact factor: 3.490

Review 6.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

7.  MexR repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa: identification of MexR binding sites in the mexA-mexR intergenic region.

Authors:  K Evans; L Adewoye; K Poole
Journal:  J Bacteriol       Date:  2001-02       Impact factor: 3.490

Review 8.  Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria.

Authors:  Hiroshi Nikaido; Jean-Marie Pagès
Journal:  FEMS Microbiol Rev       Date:  2011-07-29       Impact factor: 16.408

9.  Conjugation with polyamines enhances the antibacterial and anticancer activity of chloramphenicol.

Authors:  Ourania N Kostopoulou; Ekaterini C Kouvela; George E Magoulas; Thomas Garnelis; Ioannis Panagoulias; Maria Rodi; Georgios Papadopoulos; Athanasia Mouzaki; George P Dinos; Dionissios Papaioannou; Dimitrios L Kalpaxis
Journal:  Nucleic Acids Res       Date:  2014-06-17       Impact factor: 16.971

Review 10.  Efflux-mediated drug resistance in bacteria.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.